Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
- MHLW Ups Ante on Drug Distribution after Fake Harvoni Issue
February 17, 2017
- Council OKs Public Knowledge-Based Applications for Rituxan, Ovisot
February 17, 2017
- MHLW Council Recognizes High Medical Need for 4 APIs/5 Products Including Extended-Release Levodopa/Carbidopa Combo
February 17, 2017
- MHLW Council Discusses Issue of Development Requests for Drugs with Low NHI Prices, Few Patients
February 17, 2017
- With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
- Optimal Use Guidelines Issued for Opdivo, Keytruda for Melanoma, NSCLC Use
February 15, 2017
- Label Changes Ordered for Atarax, Zelboraf on New ADRs
February 15, 2017
- MHLW Mulls Administrative Penalties, Tighter Regulations after Counterfeit Harvoni Case
February 14, 2017
- Ex-LDP Health Panel Chief Calls for Changing Copay Rates for Different Drugs
February 13, 2017
- Zoster Vaccine’s Add’l Use, DPT Vaccine’s Booster Dose Put Under Continued Discussion for Public Immunization Program
February 13, 2017
- PMDA Eyes 15-20% New Drug Review Fee Raise in April, Plan Now Up for Public Comments
February 13, 2017
- Japan’s First Guidance for Development of Cancer Immunotherapies Will Promote Development
February 13, 2017
- Drugs Subject to Optimal Use Guidelines Will Be a Rarity: Mori
February 13, 2017
- MHLW Weighs Use of Medical Bill Database for 4 Times Yearly Price Review: Nakayama
February 10, 2017
- MHLW Councilor Cites Cancer Meds for Conditional Early Approval Scheme
February 10, 2017
- MHLW Advisory Committee Backs Shionogi’s OIC Drug
February 10, 2017
- Post-Marketing Conditions Under “Conditional Early Approval System” Remain Unclear: MHLW Councilor Kazuhiko Mori
February 10, 2017
- 2nd Batch of Sakigake Designation Slated for Spring
February 9, 2017
- Chuikyo Panel to Draw Conclusion by Summer for FY2018 Rollout of Cost-Effective Assessment Scheme
February 9, 2017
ページ
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…